[Evaluation of integrated lupus ratio test]

Improving the diagnostic strategy of the lupus anticoagulant is prerequisite in hemostasis. The objective of our work is to develop and evaluate the three integrated tests expressed as normalized ratio or Lupus Ratio and can combine the various stages in the diagnosis of these antibodies. Three Lupus Ratio are used, they were determined with activator thromboplastin time, the diluted thromboplastin time and diluted Russell Viper venom time. Reference values and thresholds for positivity were determined for all tests. Our preliminary results showed concordant and discordant profiles with those previously obtained by conventional methods of detection of circulating lupus antibody type. The interest of the integrated testing is to discusse and compari our results with those of the literature. The determination of the Ratio Lupus offers compelling and promising results and allows considering, for in a short term, the replacement of conventional techniques with improved diagnosis

[Chronic myeloid leukemia and inhibitors of tyrosine kinase]

Chronic myeloid leukemia is a hematological malignancy in the group of myeloproliferative syndromes. It is characterized by the presence of an acquired genetic abnormality at the hematopoietic stem cells, the Philadelphia chromosome. Inhibitors of tyrosine kinase, whose leader is imatinib, has profoundly changed the therapeutic management and prognosis of this malignancy. The failure of imatinib treatment is due to resistance mechanisms that are not all fully characterized. However, cross and multiple resistance remain difficult to treat and require a better understanding of their mechanisms to overcome residual disease in the near future. The persistence of a long term residual disease associated with the presence of quiescent leukemic cells, and the occurrence of relapse led to the development of second and third generation inhibitors tyrosine kinase and the combination of these inhibitors with therapeutic immunomodulators such as interferon alpha, or vaccination protocols are discussed. The purpose of this review is to update on the molecular abnormalities found in chronic myeloid leukemia with emphasis on mechanisms of imatinib resistance and the current therapeutic strategy in the era of new generations of inhibitors of tyrosine kinase

[Biological diagnosis of haemophilia]

It is a constitutional hemorrhagic disease of recessive transmission linked to X chromosome. Our objective work is to index the different cases in our service. During 18 months [April 2008 - September 2009], we account 124 haemophiliac cases diagnosed in our laboratory. Our results interest a diagnosed 124 haemophiliac cases, including 99 cases of haemophilia A [79, 83%] and 25 cases of haemophilia B [20,17%]. 81 patients have an age less than 15 years old with a median of age as 13 years [limits 9 months - 39 years]. The annual incidence of haemophilia is 82 cases. 62 persons had clinical symptomatology whereas the others were asymptomatic. These symptoms were arthropathy [59, 67%], haemoarthrosis [27,4%], haematoma [4,83%], nosebleeds epistaxis, gingivorrhagia gums [4,83%] and ecchymosis [3,26%]. According to the type of haemophilia. The severe forms of haemophilia [FVIII of FIX